Cardiologists Silvio Festinese and Dimitris Richter have published a comprehensive scientific review concluding that combustion remains the primary catalyst for cardiovascular harm in tobacco users. Analyzing data from 24 distinct studies screened from 891 records, the researchers found that adult smokers who completely transition to combustion-free alternatives significantly reduce their exposure to toxic substances, though these products are not entirely safe.
The debate surrounding e-cigarettes and heated tobacco has long centered on whether all nicotine delivery systems carry equal risks. Traditional cigarettes burn tobacco, creating smoke laced with over 7,000 harmful and potentially harmful constituents. This burning process releases carbon monoxide and oxidizing gases that severely damage the heart and blood vessels.
While nicotine is highly addictive and can acutely tighten blood vessels and raise oxygen demand, the review notes its role in long-term cardiovascular toxicity is relatively limited compared to the byproducts of combustion.
Clinical evidence supports this distinction. The review highlighted a major trial involving nearly 1,000 participants. After six months, the 488 smokers who completely switched to a tobacco heating system showed statistically significant improvements in five out of eight exposure biomarkers, including carboxyhemoglobin and the tobacco-specific carcinogen NNAL. These biological changes mirror the trajectory typically seen after complete smoking cessation.
However, the researchers issued a critical warning regarding “dual use.” Fully replacing cigarettes is fundamentally different from adding a vape while continuing to smoke. Half-switching keeps the combustion element active, effectively neutralizing the cardiovascular benefits of reduced-risk products.
StagBar Vape 6in1 180K Puffs Disposable
The Stagbar 6-in-1 featuring a unique 6-flavor system and six independent mesh coils, this device allows users to switch between six distinct tastes in one sleek unit, delivering an unprecedented 180,000 puffs.
Despite the clinical data, global health authorities remain divided on how to regulate and communicate the risks of combustion-free alternatives.
| Organization | Stance on Heated Tobacco & Vaping | Key Rationale & Actions |
|---|---|---|
| US FDA | Allows narrow “reduced exposure” marketing for specific authorized products. | Renewed modified risk orders for IQOS on April 17, 2026. Emphasizes that “reduced exposure” does not mean the product is completely safe. |
| World Health Organization (WHO) | Highly restrictive; rejects the premise that lower chemical exposure automatically reduces health risks. | Focuses on the youth epidemic. Estimates from 2025 show over 100 million global vapers, including 15 million adolescents. Warns of brain development risks. |
The WHO’s caution is heavily driven by the youth vaping epidemic. A product intended as harm reduction for addicted adults becomes a severe public health crisis when adopted by teenagers. Nicotine exposure in youth can harm brain development, making the widespread accessibility of e-cigarettes a major global concern.
For individuals who do not currently smoke, the medical consensus is absolute: do not start using vapes, heated tobacco, or any nicotine products. Lower risk does not equal no risk.
For current adult smokers, the landscape is more nuanced. The ultimate health objective is total cessation of all tobacco and nicotine products, utilizing WHO-recommended support like nicotine replacement therapies and professional counseling.
- Read more: New Study Shows E-Cigarettes Linked to Lower Harmful Chemical Exposure and Better Quit Rates
However, this latest cardiological review adds significant weight to the harm reduction argument. If a smoker is unable or unwilling to quit entirely, completely abandoning combustible cigarettes for smoke-free alternatives is a pragmatic step to reduce exposure to cardiovascular toxins. The critical takeaway is that this strategy only works if the transition is absolute.
- The study was published on Advances in Clinical and Experimental Medicine.
